‘CRISPR Therapeutics could set a milestone by filing for approval before the end of 2022 with its sickle cell/beta thal treatment…’ -Tweet From Business Insider Pharma Reporter
https://twitter.com/AndrewE_Dunn/status/1473380281818443777
Cathie Wood’s ARK Invest Posts Fund Purchases For Monday, Dec. 13, 2021: SYSS, NTLA, DNA, PD, BLI, CRSP, MTLS, NVTA, VUZI, BLDE, ROKU, COIN, EDR, ONEM, SDGR, ACCD, SLGC, MASS, QSI, PSNL, PATH, TOST, HOOD, SE, NU, KTOS, AVAV
STRATASYS LTD (SSYS) - 78600
INTELLIA THERAPEUTICS INC (NTLA) - 16800
GINKGO BIOWORKS HOLDINGS INC (DNA) - 130745
PAGERDUTY INC (PD) - 24394
BERKELEY LIGHTS INC (BLI) - 29549
CRISPR THERAPEUTICS AG (CRSP) -
Cowen & Co. Initiates Coverage On CRISPR Therapeutics with Market Perform Rating
Cowen & Co. analyst Tyler Van Buren initiates coverage on CRISPR Therapeutics (NASDAQ:CRSP) with a Market Perform rating.
Jim Cramer Shares His Thoughts On Chegg, Bristol-Myers Squibb And More
On CNBC’s "Mad Money Lightning Round," Jim Cramer said with Matterport, Inc. (NASDAQ: MTTR) already moving too much, "I’m going to have to take a big pass."
Barclays Maintains Overweight on CRISPR Therapeutics, Lowers Price Target to $148
Barclays analyst Gena Wang maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Overweight and lowers the price target from $160 to $148.
CRISPR Therapeutics Q3 Sales $300.00K Up From $148.00K YoY
CRISPR Therapeutics (NASDAQ:CRSP) reported $300.00 thousand in sales this quarter. This is a 102.70 percent increase over sales of $148.00 thousand the same period last year.
SVB Leerink Initiates Coverage On CRISPR Therapeutics with Outperform Rating, Announces Price Target of $126
SVB Leerink analyst Rick Bienkowski initiates coverage on CRISPR Therapeutics (NASDAQ:CRSP) with a Outperform rating and announces Price Target of $126.
BZ Chart Of The Day: Is Crisper Therapeutics About To Rally?
Shares of CRISPR Therapeutics AG (NASDAQ: CRSP) may be forming a “V” bottom on the chart. That means the stock could rally.